• Sensex76913.5-582.86(-0.75%)
  • Nifty23997.55-180.1(-0.74%)
  • USDINR94.790.27(0.28%)
Online tarding Partner With Us
BSE Prices delayed by 5 minutes ! Prices as on   Apr 30, 2026   ABB India 7229.05 [ -0.49% ]ACC 1422.65 [ -0.97% ]Ambuja Cements 444.5 [ -2.28% ]Asian Paints 2444.6 [ -0.11% ]Axis Bank 1267.7 [ -2.14% ]Bajaj Auto 9997.75 [ 4.78% ]Bank of Baroda 263.5 [ -1.77% ]Bharti Airtel 1886.05 [ -0.10% ]Bharat Heavy 352.4 [ 2.31% ]Bharat Petroleum 300.45 [ -1.15% ]Britannia Industries 5725.9 [ 0.28% ]Cipla 1309.9 [ -0.51% ]Coal India 481.35 [ 0.35% ]Colgate Palm 2096.75 [ -1.66% ]Dabur India 441.5 [ -3.18% ]DLF 587.15 [ -1.15% ]Dr. Reddy's Lab. 1322.95 [ -0.54% ]GAIL (India) 163.4 [ -1.39% ]Grasim Industries 2792.6 [ -0.34% ]HCL Technologies 1198.95 [ -0.06% ]HDFC Bank 771.2 [ -0.98% ]Hero MotoCorp 5100.45 [ -0.22% ]Hindustan Unilever 2250.6 [ -2.70% ]Hindalco Industries 1037.3 [ -2.82% ]ICICI Bank 1262.75 [ -1.39% ]Indian Hotels Co. 635.75 [ -1.32% ]IndusInd Bank 915.55 [ 0.21% ]Infosys 1181.5 [ 1.20% ]ITC 314.95 [ -0.40% ]Jindal Steel 1223.85 [ -0.40% ]Kotak Mahindra Bank 382.65 [ 0.28% ]L&T 4012.65 [ -2.03% ]Lupin 2303.7 [ -0.31% ]Mahi. & Mahi 3096.9 [ -1.71% ]Maruti Suzuki India 13312.85 [ 0.40% ]MTNL 31.18 [ -0.83% ]Nestle India 1457.8 [ -0.57% ]NIIT 69.82 [ -1.29% ]NMDC 90.33 [ -1.57% ]NTPC 399.15 [ -0.50% ]ONGC 299.35 [ -0.65% ]Punj. NationlBak 109.35 [ -1.62% ]Power Grid Corpn. 318.25 [ -0.66% ]Reliance Industries 1430.85 [ 0.33% ]SBI 1068 [ -1.69% ]Vedanta 271.6 [ -64.88% ]Shipping Corpn. 304.9 [ -0.93% ]Sun Pharmaceutical 1808.2 [ 1.64% ]Tata Chemicals 809.45 [ 1.14% ]Tata Consumer 1144.45 [ -2.02% ]Tata Motors Passenge 341.6 [ -3.05% ]Tata Steel 211.3 [ -2.13% ]Tata Power Co. 444.55 [ -1.60% ]Tata Consult. Serv. 2473.5 [ 0.01% ]Tech Mahindra 1474.05 [ 0.95% ]UltraTech Cement 11582.8 [ -2.08% ]United Spirits 1325.4 [ -2.72% ]Wipro 200.65 [ -0.02% ]Zee Entertainment 89.78 [ -0.75% ]
BSE

MARKETS

News Details

( As on 23/04/2026 11:09)

Cipla Limited gets USFDA nod for first generic of Ventolin HFA

Cipla Limited, along with its subsidiary Cipla USA Inc., has received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol (90 mcg).

The approval marks the launch of the first AB-rated generic equivalent of Ventolin HFA, originally marketed by GlaxoSmithKline. The inhaler is used to treat and prevent bronchospasm in patients aged four years and above, including those with reversible airway diseases and exercise-induced bronchospasm.

With the U.S. albuterol market estimated at around $1.5 billion, this approval strengthens Cipla’s respiratory portfolio and solidifies its presence in the inhalation segment, where it now offers generics for both Ventolin HFA and Proventil HFA.

Managing Director and Global CEO Achin Gupta said the milestone highlights the company’s strong capabilities in complex inhalation therapies and its commitment to expanding a differentiated global respiratory portfolio.

The product will be manufactured at Cipla’s dedicated inhalation facility in Fall River, Massachusetts, supporting its strategy to enhance supply resilience and expand its U.S. manufacturing footprint.